Consolidated Statements Of Operations (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Revenue
Blood products	$ 7,176,000	$ 7,525,000
Therapeutic services	9,069,000	7,711,000
Total revenue	16,245,000	15,236,000
Cost of sales
Blood products	7,666,000	7,528,000
Therapeutic services	6,221,000	5,459,000
Total cost of sales	13,887,000	12,987,000
Gross profit	2,358,000	2,249,000
General and administrative expenses	4,707,000	4,881,000
Loss from operations	(2,349,000)	(2,632,000)
Gain on insurance settlement	192,000
Loss from continuing operations before tax	(2,157,000)	(2,632,000)
Provision for (benefit of) income taxes	10,000	(60,000)
Loss from continuing operations, net of tax	(2,167,000)	(2,572,000)
Income from discontinued operations	1,362,000	1,776,000
Net loss	$ (805,000)	$ (796,000)
Basic
Continuing operations	$ (0.22)	$ (0.26)
Discontinued operations	$ 0.14	$ 0.18
Total	$ (0.08)	$ (0.08)
Diluted
Continuing operations	$ (0.22)	$ (0.26)
Discontinued operations	$ 0.13	$ 0.18
Total	$ (0.08)	$ (0.08)
Weighted average shares outstanding-basic	9,957,474	9,968,120
Weighted average shares outstanding-diluted	10,196,474	10,139,120